Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Todd Davies, PhD

Janssen Research & Development

Disclosure(s): Janssen: Employee of Janssen Research & Development

Poster(s):

120 - Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET